Xeureka & UBE launch joint cancer drug discovery program

Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress

Sai Life Sciences unveils 2024–25 sustainability report

The company also reported significant progress toward its internally defined Sustainable Development Goals

UK to get groundbreaking early detection test for bowel cancer

Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status

Samsung Biologics strengthens U.S. presence with acquisition of GSK’s Human Genome Sciences or $280 million

Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs

SandboxAQ, MapLight team up to target novel CNS therapy with AI-driven drug discovery

SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements

Zydus signs exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India

Takeda joins BaseLaunch to boost early-stage biotech ventures in Europe

BaseLaunch has supported 27 biotech companies across multiple modalities and indications

GenSci, RTW & Yarrow Bioscience strike $1.365 billion global deal for breakthrough graves’ disease therapy

GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies

Godavari Biorefineries launches US biotech arm to advance novel cancer therapies

The move strengthens GBL’s clinical-stage presence in the United States

Glenmark secures exclusive multi-regional rights to Aumolertinib from Hansoh Pharma

Hansoh Pharma will receive an upfront payment in the low double-digit millions